Login Register Cart 0
Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Three Generation β-Blockers for Atrial Fibrillation Treatment

Author(s): Arthur C. Francisco, Wanessa M. C. Awata, Thauann S. Lima, Simone R. Potje, Clare C. Prohaska, Carla S. Ceron and Gabriel T. do Vale*

Volume 19, Issue 1, 2023

Published on: 03 October, 2022

Page: [34 - 41] Pages: 8

DOI: 10.2174/1573402118666220609161044

Price: $65

Abstract

The efficiency of blood flowing from the heart depends on its electrical properties. Myocardial electrical activity is associated with generating cardiac action potentials in isolated myocardial cells and their coordinated propagation, which are mediated by gap junctions. Atrial fibrillation (AF) is a common cardiac arrhythmia which causes an aggressive disturbance in cardiac electromechanical function. Moreover, AF increases the risk of stroke and mortality and is a major cause of death. The mechanisms underlying AF involve electrophysiological changes in ion channel expression and function. β-blockers may be useful in patients with chronic AF or in preventing postoperative AF in subjects undergoing coronary artery bypass grafting (CABG) or other types of surgery. The reduction in heart rate induced by β1-adrenergic receptor antagonists may be associated with the beneficial effect of this drug class. Second generation beta-blockers may be considered superior to the first generation due to their selectivity to the β1 receptor as well as avoiding pulmonary or metabolic adverse effects. Third generation beta-blockers may be considered a great option for their vasodilation and antioxidant properties. There is also a new β-blocker, named landilol that also results on reduced risk of post operative AF without adverse effects and its use has been increasing in clinical trials.

Keywords: β-blocker, New β-blocker, β-adrenergic receptor, β1-adrenergic receptor antagonist, atrial fibrillation, myocardiocytes.

« Previous Next »
[1]
Sundjaja JH, Bordoni B. Anatomy, Thorax, Heart Pulmonic Valve. Treasure Island, FL: StatPearls Publishing 2021.
[2]
Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 2001; 10(4): 169-77.
[http://dx.doi.org/10.1016/S1054-8807(01)00078-3] [PMID: 11600334]
[3]
Antzelevitch C, Dumaine R. Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. Handbook of Physiology. The Cardiovascular System. Heart 2002; 2(1): 654-92.
[4]
Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: Their regulation and functions. Physiol Rev 2003; 83(4): 1359-400.
[http://dx.doi.org/10.1152/physrev.00007.2003] [PMID: 14506308]
[5]
Nerbonne JM. Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms? Trends Cardiovasc Med 2004; 14(3): 83-93.
[http://dx.doi.org/10.1016/j.tcm.2003.12.006] [PMID: 15121155]
[6]
Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005; 85(4): 1205-53.
[http://dx.doi.org/10.1152/physrev.00002.2005] [PMID: 16183911]
[7]
Nerbonne JM, Guo W. Heterogeneous expression of voltage-gated potassium channels in the heart: Roles in normal excitation and arrhythmias. J Cardiovasc Electrophysiol 2002; 13(4): 406-9.
[http://dx.doi.org/10.1046/j.1540-8167.2002.00406.x] [PMID: 12033361]
[8]
Antzelevitch C. Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. J Cardiovasc Electrophysiol 2003; 14(11): 1259-72.
[http://dx.doi.org/10.1046/j.1540-8167.2003.03316.x] [PMID: 14678150]
[9]
Kléber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004; 84(2): 431-88.
[http://dx.doi.org/10.1152/physrev.00025.2003] [PMID: 15044680]
[10]
Delmar M. Role of potassium currents on cell excitability in cardiac ventricular myocytes. J Cardiovasc Electrophysiol 1992; 3(5): 474-86.
[http://dx.doi.org/10.1111/j.1540-8167.1992.tb00990.x]
[11]
Clancy CE, Tateyama M, Kass RS. Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J Clin Invest 2002; 110(9): 1251-62.
[http://dx.doi.org/10.1172/JCI0215928] [PMID: 12417563]
[12]
Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res 1994; 74(6): 1071-96.
[http://dx.doi.org/10.1161/01.RES.74.6.1071] [PMID: 7514509]
[13]
Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ Res 1994; 74(6): 1097-113.
[http://dx.doi.org/10.1161/01.RES.74.6.1097] [PMID: 7514510]
[14]
Fozzard HA. Excitation-contraction coupling in the heart. Adv Exp Med Biol 1991; 308: 135-42.
[http://dx.doi.org/10.1007/978-1-4684-6015-5_11] [PMID: 1666263]
[15]
Fozzard HA. Cardiac sodium and calcium channels: A history of excitatory currents. Cardiovasc Res 2002; 55(1): 1-8.
[http://dx.doi.org/10.1016/S0008-6363(02)00407-8] [PMID: 12062702]
[16]
Fabiato A, Fabiato F. Calcium and cardiac excitation-contraction coupling. Annu Rev Physiol 1979; 41(1): 473-84.
[http://dx.doi.org/10.1146/annurev.ph.41.030179.002353] [PMID: 373601]
[17]
Bers DM, Perez-Reyes E. Ca channels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release. Cardiovasc Res 1999; 42(2): 339-60.
[http://dx.doi.org/10.1016/S0008-6363(99)00038-3] [PMID: 10533572]
[18]
Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009; 27(1): 13-24.
[http://dx.doi.org/10.1016/j.ccl.2008.09.015] [PMID: 19111760]
[19]
Zimetbaum P. Atrial fibrillation. Ann Intern Med 2017; 166(5): ITC33-48.
[http://dx.doi.org/10.7326/AITC201703070] [PMID: 28265666]
[20]
Piña PG, Chicos AB. Early cardioversion in atrial fibrillation: Earlier is better, but not always and (maybe) not immediately. Curr Atheroscler Rep 2017; 19(1): 3.
[http://dx.doi.org/10.1007/s11883-017-0638-1] [PMID: 28108860]
[21]
Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89(1): 224-7.
[http://dx.doi.org/10.1161/01.CIR.89.1.224] [PMID: 8281651]
[22]
Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: The Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J 2006; 152(6): 1097-103.
[http://dx.doi.org/10.1016/j.ahj.2006.08.011] [PMID: 17161061]
[23]
Zimetbaum P, Goldman A. Ambulatory arrhythmia monitoring: Choosing the right device. Circulation 2010; 122(16): 1629-36.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.925610] [PMID: 20956237]
[24]
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370(26): 2478-86.
[http://dx.doi.org/10.1056/NEJMoa1313600] [PMID: 24963567]
[25]
Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003; 305(3): 800-11.
[http://dx.doi.org/10.1124/jpet.103.049270] [PMID: 12649306]
[26]
Audigane L, Kerfant BG, El Harchi A, et al. Rabbit, a relevant model for the study of cardiac beta 3-adrenoceptors. Exp Physiol 2009; 94(4): 400-11.
[http://dx.doi.org/10.1113/expphysiol.2008.045179] [PMID: 19151075]
[27]
Galougahi KK, Liu CC, Bundgaard H, Rasmussen HH. β-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling. Trends Cardiovasc Med 2012; 22(4): 83-7.
[http://dx.doi.org/10.1016/j.tcm.2012.06.017] [PMID: 23040838]
[28]
do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β-blockers: History, class differences and clinical applicability. Curr Hypertens Rev 2019; 15(1): 22-31.
[http://dx.doi.org/10.2174/1573402114666180918102735] [PMID: 30227820]
[29]
Najafi A, Sequeira V, Kuster DWD, van der Velden J. β-adrenergic receptor signalling and its functional consequences in the diseased heart. Eur J Clin Invest 2016; 46(4): 362-74.
[http://dx.doi.org/10.1111/eci.12598] [PMID: 26842371]
[30]
Post SR, Hammond HK, Insel PA. Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 1999; 39(1): 343-60.
[http://dx.doi.org/10.1146/annurev.pharmtox.39.1.343] [PMID: 10331088]
[31]
Kaumann AJ, Hall JA, Murray KJ, Wells FC, Brown MJ. A comparison of the effects of adrenaline and noradrenaline on human heart: The role of β 1- and β 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 1989; 10 (Suppl. B): 29-37.
[http://dx.doi.org/10.1093/eurheartj/10.suppl_B.29] [PMID: 2572419]
[32]
Berg T. Beta1-blockers lower norepinephrine release by inhibiting presynaptic, facilitating β1-adrenoceptors in normotensive and hypertensive rats. Front Neurol 2014; 5: 51.
[http://dx.doi.org/10.3389/fneur.2014.00051] [PMID: 24795691]
[33]
Johnson JA, Davis JO, Gotshall RW, et al. Evidence for an intrarenal beta receptor in control of renin release. Am J Physiol 1976; 230(2): 410-8.
[http://dx.doi.org/10.1152/ajplegacy.1976.230.2.410] [PMID: 1259022]
[34]
Barroso WKS, Rodrigues CIS, Bortolotto LA, et al. Brazilian guidelines of hypertension – 2020. Arq Bras Cardiol 2021; 116(3): 516-58.
[35]
Reiter MJ. Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis 2004; 47(1): 11-33.
[http://dx.doi.org/10.1016/j.pcad.2004.04.004] [PMID: 15517513]
[36]
Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet 1964; 1(7342): 1080-1.
[http://dx.doi.org/10.1016/S0140-6736(64)91275-9] [PMID: 14132613]
[37]
Hansson L, Zweifler AJ. The effct of propranolol on plasma renin activity and blood pressure in mild essential hypertension. Acta Med Scand 1974; 195(5): 397-401.
[PMID: 4598059]
[38]
Boskabady MH, Snashall PD. Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta-blockade in asthma. Respirology 2000; 5(2): 111-8.
[http://dx.doi.org/10.1046/j.1440-1843.2000.00236.x] [PMID: 10894099]
[39]
Marsden CD, Foley TH, Owen DA, McAllister RG. Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci 1967; 33(1): 53-65.
[PMID: 6059304]
[40]
Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet 1979; 1(8114): 458-62.
[http://dx.doi.org/10.1016/S0140-6736(79)90821-3] [PMID: 85053]
[41]
Kerr D, MacDonald IA, Heller SR, Tattersall RB. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990; 29(6): 685-93.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03689.x] [PMID: 1974143]
[42]
Harrison DC, Griffin JR, Fiene TJ. Effects of beta-adrenergic blockade with propranolol in patients with atrial arrhythmias. N Engl J Med 1965; 273(8): 410-5.
[http://dx.doi.org/10.1056/NEJM196508192730802] [PMID: 14328103]
[43]
Kojuri J, Mahmoodi Y, Jannati M, Shafa M, Ghazinoor M, Sharifkazemi MB. Ability of amiodarone and propranolol alone or in combination to prevent post-coronary bypass atrial fibrillation. Cardiovasc Ther 2009; 27(4): 253-8.
[http://dx.doi.org/10.1111/j.1755-5922.2009.00100.x] [PMID: 19903189]
[44]
Blessberger H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery. Cochrane Database Syst Rev 2019; 9CD013435
[PMID: 31544227]
[45]
Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother 1968; 32(1): 201-18.
[http://dx.doi.org/10.1111/j.1476-5381.1968.tb00444.x] [PMID: 4384337]
[46]
Pribble AH, Conn RD. The use of practolol in supraventricular arrhythmias associated with acute illnesses. Am J Cardiol 1975; 35(5): 645-50.
[http://dx.doi.org/10.1016/0002-9149(75)90050-8] [PMID: 1124718]
[47]
Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest 1977; 71(5): 592-6.
[http://dx.doi.org/10.1378/chest.71.5.592] [PMID: 856557]
[48]
Barrett AM, Carter J, Fitzgerald JD, Hull R, Le Count D. A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol 1973; 48(2): 340P.
[PMID: 4147428]
[49]
Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13(1): 1-6.
[http://dx.doi.org/10.1097/00005344-198901000-00002] [PMID: 2468920]
[50]
Matangi MF, Strickland J, Garbe GJ, et al. Atenolol for the prevention of arrhythmias following coronary artery bypass grafting. Can J Cardiol 1989; 5(4): 229-34.
[PMID: 2659151]
[51]
Ablad B, Carlsson E, Ek L. Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. Life Sci I 1973; 12(3): 107-19.
[http://dx.doi.org/10.1016/0024-3205(73)90368-8] [PMID: 4144510]
[52]
Sandberg F, Corino VD, Mainardi LT, et al. Non-invasive assessment of the effect of beta blockers and calcium channel blockers on the AV node during permanent atrial fibrillation. J Electrocardiol 2015; 48(5): 861-6.
[http://dx.doi.org/10.1016/j.jelectrocard.2015.07.019] [PMID: 26275982]
[53]
Silvet H, Hawkins LA, Jacobson AK. Heart rate control in patients with chronic atrial fibrillation and heart failure. Congest Heart Fail 2013; 19(1): 25-8.
[http://dx.doi.org/10.1111/j.1751-7133.2012.00309.x] [PMID: 22958623]
[54]
Kamali A, Sanatkar A, Sharifi M, Moshir E. Evaluation of amiodarone versus metoprolol in treating atrial fibrillation after coronary artery bypass grafting. Interv Med Appl Sci 2017; 9(2): 51-5.
[http://dx.doi.org/10.1556/1646.9.2017.11] [PMID: 28932497]
[55]
Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004; 93(9A): 3B-6B.
[http://dx.doi.org/10.1016/j.amjcard.2004.01.003] [PMID: 15144929]
[56]
Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007; 9(4): 269-77.
[http://dx.doi.org/10.1007/s11906-007-0050-2] [PMID: 17686376]
[57]
De Cree J, Van Nueten L, Geukens H, Verhaegen H. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 1992; 12(4): 159-63.
[PMID: 1363660]
[58]
Farmer JB, Kennedy I, Levy GP, Marshall RJ. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol 1972; 45(4): 660-75.
[http://dx.doi.org/10.1111/j.1476-5381.1972.tb08125.x] [PMID: 4404413]
[59]
Carvalho TM, Cavalli RC, Marques MP, Da Cunha SP, Baraldi CO, Lanchote VL. Stereoselective analysis of labetalol in human plasma by LC-MS/MS: Application to pharmacokinetics. Chirality 2009; 21(8): 738-44.
[http://dx.doi.org/10.1002/chir.20673] [PMID: 19006203]
[60]
Krumpl G, Todt H, Krejcy K, Raberger G. Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation. Br J Pharmacol 1990; 100(4): 855-61.
[http://dx.doi.org/10.1111/j.1476-5381.1990.tb14104.x] [PMID: 2207504]
[61]
Wong CK, Lau CP, Leung WH, Cheng CH. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol 1990; 66(17): 1212-5.
[http://dx.doi.org/10.1016/0002-9149(90)91102-C] [PMID: 2239725]
[62]
Gheorghiade M, Lukas MA, Lukas MA. Role of carvedilol in atrial fibrillation: Insights from clinical trials. Am J Cardiol 2004; 93(9A): 53B-7B.
[http://dx.doi.org/10.1016/j.amjcard.2004.01.023] [PMID: 15144939]
[63]
Kodani E, Matsumoto S, Igawa O, Kusama Y, Atarashi H. Effect of carvedilol on reduction in heart rate in patients with chronic atrial fibrillation. J Clin Med Res 2013; 5(6): 451-9.
[http://dx.doi.org/10.4021/jocmr1581w] [PMID: 24171057]
[64]
Chitrapu RV, Rao PR, Reddy GV. Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation. J Pharmacol Pharmacother 2014; 5(4): 239-44.
[http://dx.doi.org/10.4103/0976-500X.142430] [PMID: 25422563]
[65]
Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal β-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: Carvedilol versus metoprolol. Heart Rhythm 2007; 4(9): 1170-4.
[http://dx.doi.org/10.1016/j.hrthm.2007.04.022] [PMID: 17765616]
[66]
Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11(5): 552-63.
[http://dx.doi.org/10.1097/00005344-198805000-00007] [PMID: 2455841]
[67]
Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38(3): 199-204.
[http://dx.doi.org/10.1111/j.1365-2125.1994.tb04342.x] [PMID: 7826820]
[68]
Vanhoutte PM, Gao Y. Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013; 13(2): 265-73.
[http://dx.doi.org/10.1016/j.coph.2012.12.002] [PMID: 23294896]
[69]
Howlett JG, Howlett MD. Nebivolol: Vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol 2014; 30(5) (Suppl.): S29-37.
[http://dx.doi.org/10.1016/j.cjca.2014.03.003] [PMID: 24750980]
[70]
Cicero AFG, Kuwabara M, Borghi C. A critical review of nebivolol and its fixed-dose combinations in the treatment of hypertension. Drugs 2018; 78(17): 1783-90.
[http://dx.doi.org/10.1007/s40265-018-0999-y] [PMID: 30426333]
[71]
Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol 2019; 125(3): 189-201.
[http://dx.doi.org/10.1111/bcpt.13248] [PMID: 31066991]
[72]
Shubik IuV, Medvedev MM, Kriatova TV. Heart rate control with nebivolol in patients with tachysystolic atrial fibrillation. Kardiologiia 2003; 43(9): 52-5.
[PMID: 14593370]
[73]
Tepliakov AT, Kuznetsova AV, Lukinov AV, Levshin AV. Effects of a superselective beta1-adrenoblocker nebivolol on the course of coronary heart disease and insulin resistance in patients with diabetes mellitus type 2 after coronary artery bypass grafting. Ter Arkh 2007; 79(12): 38-43.
[PMID: 18220029]
[74]
Erdil N, Kaynak M, Dönmez K, Disli OM, Battaloglu B. Nebivolol in preventing atrial fibrillation following coronary surgery in patients over 60 years of age. Rev Bras Cir Cardiovasc 2014; 29(4): 581-7.
[http://dx.doi.org/10.5935/1678-9741.20140078] [PMID: 25714213]
[75]
Nakano T, Shimizu K, Kawashima O, et al. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther 2012; 37(4): 431-5.
[http://dx.doi.org/10.1111/j.1365-2710.2011.01315.x] [PMID: 22059486]
[76]
Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial. J Thorac Cardiovasc Surg 2011; 141(6): 1478-87.
[http://dx.doi.org/10.1016/j.jtcvs.2010.10.045] [PMID: 21269646]
[77]
Balik M, Sander M, Trimmel H, Heinz G. Landiolol for managing post-operative atrial fibrillation. Eur Heart J Suppl 2018; 20 (Suppl. A): A10-4.
[http://dx.doi.org/10.1093/eurheartj/sux036] [PMID: 30188958]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy